Why the study?
Patients with VTE face short-term and long-term complications affecting function and quality of life, and clinicians need guidance on when to escalate to thrombolytic therapy.
Does thrombolytic therapy improve clinical outcomes in patients with acute pulmonary embolism and deep vein thrombosis?
Does thrombolytic therapy improve clinical outcomes in patients with acute pulmonary embolism and deep vein thrombosis?
This guidance document provides consensus-based recommendations for risk stratification and the individualized use of systemic and catheter-directed thrombolysis in patients with acute PE and DVT.
No takes yet. Share an insight, caveat, or question.
Requires individualized VTE thrombolysis decisions; leaves open optimal strategies pending randomized validation.
Vedantham et al. (2016) conducted a review in Venous thromboembolism (VTE). Thrombolytic therapy vs. Anticoagulation alone was evaluated. Thrombolytic therapy for venous thromboembolism requires individualized risk stratification, with pharmacomechanical catheter-directed thrombolysis suggested for acute DVT and systemic or catheter-directed options for massive or submassive PE.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: